Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5790966 | 0.92 | TGFBR1 (0.44) | TGFBR1KDRMAPK14GAAMAPT | |
| SCHEMBL5789640 | 0.87 | TGFBR1 (0.49) | TGFBR1MAPKAPK2KDRMAPK14JAK2 | |
| SCHEMBL5791728 | 0.85 | SMN1; SMN2 (0.49) | TGFBR1MAPKAPK2KDRDYRK1AMAPK14 | |
| SCHEMBL5789395 | 0.84 | TGFBR1 (0.48) | TGFBR1KDRMAPK14JAK2JAK1 | |
| SCHEMBL5791430 | 0.83 | SLC2A1 (0.50) | TGFBR1 | |
| SCHEMBL5788683 | 0.81 | USP7 (0.48) | TGFBR1KDRMAPK14GAAMAPT | |
| SCHEMBL5789604 | 0.79 | TGFBR1 (0.43) | TGFBR1KDRMAPK14GAAMAPT | |
| SCHEMBL5907467 | 0.78 | TGFBR1 (0.54) | TGFBR1MAPKAPK2KDRDYRK1AMAPK14 | |
| SCHEMBL5791586 | 0.78 | TGFBR1 (0.59) | TGFBR1KDRMAPK14GAAMAPT | |
| SCHEMBL5907462 | 0.78 | TGFBR1 (0.55) | TGFBR1MAPKAPK2KDRDYRK1AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1543003-B1 | IMIDAZO¬1,2-A|PYRIDINES | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050234029-A1 | Compounds | DODIC NERINA | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234029-A1 | Compounds | SMAD3, SMAD2, ACVR1 | TGFBR1 4/4885MAPKAPK2 81/4885KDR 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.